Skip to Content

Vertex Pharmaceuticals Inc - Stock Quote VRTX

Rating as of

Morningstar's Vertex Pharmaceuticals Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Narrow-Moat Vertex Reports Strong Q1 Results; Maintaining $293 FVE, Shares Undervalued

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Vertex reported strong first-quarter results highlighted by nearly $2.1 billion in product revenue, representing a 22% increase from the prior year period. We’ve updated our valuation model, and we maintain our fair value estimate of $293 per share and continue to view shares as undervalued. The stock is currently trading in 4-star territory about 14% below our fair value estimate. We maintain our narrow economic moat and positive trend ratings, which are supported by intangible assets and its diversified pipeline spanning six disease areas.

Read Full Analysis

Vertex Pharmaceuticals Inc's Company Profile

Business Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Contact
50 Northern Avenue
Boston, MA, 02210
T +1 617 341-6100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 3,900

Vertex Pharmaceuticals Inc's Related Articles & News